SMA REACH UK
  • Home
  • For Patients and Parents
  • For Researchers
    • SMA REACH UK information
    • SMA REACH UK Centre
    • Physiotherapy
    • Study documents
  • Meet the Team
  • News and Updates
  • Contact
  • SMA Fatigability Survey
  • More
    • Home
    • For Patients and Parents
    • For Researchers
      • SMA REACH UK information
      • SMA REACH UK Centre
      • Physiotherapy
      • Study documents
    • Meet the Team
    • News and Updates
    • Contact
    • SMA Fatigability Survey
SMA REACH UK
  • Home
  • For Patients and Parents
  • For Researchers
    • SMA REACH UK information
    • SMA REACH UK Centre
    • Physiotherapy
    • Study documents
  • Meet the Team
  • News and Updates
  • Contact
  • SMA Fatigability Survey

SMA Research And Clinical Hub UK

SMA Research And Clinical Hub UKSMA Research And Clinical Hub UKSMA Research And Clinical Hub UK

SMA Research And Clinical Hub UK

SMA Research And Clinical Hub UKSMA Research And Clinical Hub UKSMA Research And Clinical Hub UK

About SMA REACH UK

Spinal Muscular Atrophy (SMA) is an autosomal recessive genetic disease that affects the motor neurons of the voluntary muscles that are used for activities such as crawling, walking, head and neck control, and swallowing. 


Approximately 1 in 6000 babies born are affected and about 1 in 40 people are genetic carriers. Childhood SMA can be divided into three subtypes depending on disease onset and severity. All subtypes result in the degeneration of motor neurons controlling voluntary muscles with proximal limb and trunk muscle weakness leading to respiratory distress and in the most severe cases, ultimately death.

 Recent advances into drug development have resulted in specific drug treatments becoming available for SMA. Other compounds are also under investigation via clinical trials. Over the last few years, this has considerably pushed the need to monitor clinical and cost effectiveness of the therapies and to be prepared for further clinical trials. The SMA Research and Clinical Hub UK – SMA REACH UK – provides the ongoing necessary robust clinical and research network to design and improve upon outcome measures that will capture clinical effectiveness and be meaningful and suitable for both people who have SMA as well as for clinical trials

 SMA REACH UK is involved with an international initiative called ISMAC (International SMA Consortium) with two prestigious Networks: the Paediatric Neuromuscular Clinical Research Network in the United States (Principal Investigator Richard Finkel) and the Italian SMA Network (Principle Investigator Eugenio Mercuri). 


The consortium is in collaboration with Biogen to collect anonymised natural history data of SMA patients covering the entire spectrum of SMA severity.


SMA REACH UK is also supported by SMA UK, Muscular Dystrophy UK and Treat SMA charities.

Our Mission

Our mission is to establish the first national clinical and research network named SMA REACH UK (SMA Research And Clinical Hub UK). SMA REACH UK has been designed, piloted and are expanding this electronic database. The database streamlines the collection of data for paediatric patients across the UK and aim to continue this in the future

Aims and objectives

SMA REACH UK aim to utilize streamlined assessment tools throughout the SMA community to accomplish the following objectives:

  1. To be an effective database to collect safety and efficacy data for available and future treatments; some of which may be provided to NICE,NHS England and companies developing the treatments in an anonymised form.
  2. Continued natural history data collection of SMA  patients.
  3. Supporting the development and transfer of paediatric patients to the adult SMA REACH network without loss of data.
  4. To enable the collection of Parent/Patient-Reported Outcomes Measures using an effective questionnaire method. This data will provide information about aspects on the daily life and general well-being of patients with SMA.


Furthermore, we aspire to develop national agreements for SMA patients on


- clinical assessment

- physiotherapy assessment

- treatment for SMA patients

- standards of care for SMA patients



  • Home
  • Privacy Policy

SMA REACH UK

UCL Great Ormond Street Institute of Child Health

Copyright © 2022 SMA REACH UK - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept

Latest News and Updates

Zolgensma Treatment Updates from Health Professionals


New SMA REACH article publication on 

Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement


Webinar with Graeme O’Connor on a recent pilot project on amino acid diet

Read more